Astrana Health, Inc. (ASTH) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Astrana Health, Inc. is a physician-centric, technology-powered, risk-bearing healthcare company operating three reportable segments: Care Partners, Care Delivery, and Care Enablement. As of year-end, the company coordinated care for approximately 1.6 million patients through a network of over 20,000 contracted physicians. A defining event of the period was the acquisition of certain businesses and assets of Prospect Medical Holdings, Inc. ("Prospect") on July 1, 2025, for a purchase price of $674.9 million, significantly expanding the company's provider network and geographic footprint.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $3,181.8 million | $2,034.5 million | +56% |
| Net Income (GAAP) | $24.1 million | $49.9 million | -52% |
| Net Income Attributable to Astrana | $22.5 million | $43.1 million | -48% |
| Adjusted EBITDA | $205.4 million | $170.4 million | +21% |
| Adjusted EBITDA Margin | 6.0% | 8.0% | -200 bps |
| Free Cash Flow | $104.5 million | $44.2 million | +136% |
| Total Debt (Outstanding) | $1,052.2 million | $438.1 million | +140% |
| Cash and Cash Equivalents | $429.5 million | $288.5 million | +49% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $1.15 billion (56%), driven primarily by the Prospect acquisition (contributing ~$616 million) and organic growth in capitation revenue due to prior acquisitions and members transitioning to full risk.
- Profitability Decline: Despite revenue growth, Net Income attributable to Astrana decreased by 48%. This was caused by a decrease in operating income (due to higher utilization and G&A expenses) and a significant increase in interest expense ($49.9 million vs. $33.1 million) resulting from debt incurred to finance the Prospect acquisition.
- Segment Performance:
- Care Partners: Revenue increased 55% to $3.02 billion; Operating income increased 10% to $155.0 million.
- Care Delivery: Revenue increased 83% to $250.7 million; Operating income turned negative ($-2.0 million) due to growth-related expenses.
- Care Enablement: Revenue increased 59% to $246.7 million; Operating income increased 117% to $39.7 million.
- Debt Structure: The company entered into a Second Amended and Restated Credit Agreement in February 2025 and drew down $707.3 million in July 2025 to fund the Prospect acquisition, increasing total debt from $438.1 million to $1.05 billion.
Guidance, Outlook, Risks, and Unusual Items
- Internal Control Material Weakness: The company identified a material weakness in internal control over financial reporting related to accounting for business combinations. Specifically, controls were insufficient to ensure the completeness and accuracy of net working capital determinations during acquisitions. Consequently, the independent auditor issued an adverse opinion on the effectiveness of internal control over financial reporting.
- Regulatory Risks: The company faces risks related to the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025, which introduces Medicaid work requirements and tighter provider tax rules. Additionally, the company is subject to extensive federal and state regulations regarding the corporate practice of medicine, False Claims Act, and Anti-Kickback Statutes.
- Integration Risks: Significant risks exist regarding the successful integration of the Prospect acquisition, including operational challenges, retention of key personnel, and the management of a newly acquired acute care hospital (Foothill Regional Medical Center), which is a new business line for Astrana.
- Unusual Items: The company recognized a $13.0 million loss contingency in Q3 2025 related to a legal matter with a provider associated with CFC Health Plan. Additionally, $25.9 million in transaction and integration costs related to the Prospect acquisition were expensed.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for the material weakness in accounting for business combinations and the timeline for achieving an unqualified audit opinion on internal controls.
- Debt Covenants: Review compliance with the Second Amended and Restated Credit Agreement covenants, specifically the maximum consolidated total net leverage ratio (5.00:1.00 through Q1 2027, then 4.50:1.00) and minimum interest coverage ratio (2.50:1.00).
- Prospect Integration: Assess the operational performance of the acquired Foothill Regional Medical Center and the realization of anticipated cost synergies from the Prospect acquisition.
- Regulatory Impact: Monitor the downstream effects of the OBBBA and potential changes to Medicare Advantage payment rates on the company's capitation revenue and margins.
- Medical Liabilities: Review the actuarial assumptions used for Incurred But Not Reported (IBNR) claims, which totaled $335.7 million at year-end, as this is a critical audit matter with high subjectivity.